Allos Therapeutics Company Profile (NASDAQ:ALTH)

About Allos Therapeutics (NASDAQ:ALTH)

Allos Therapeutics logoAllos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of anti-cancer therapeutics. As of December 31, 2011, the Company focused on the development and commercialization of FOLOTYN (pralatrexate injection). FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. FOLOTYN targets the inhibition of dihydrofolate reductase (DHFR), an enzyme critical in the folate pathway, thereby interfering with deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis and triggering cancer cell death. FOLOTYN can be delivered as a single agent, for which the Company has approval for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), and can be used in combination therapy regimens. On September 5, 2012, Spectrum Pharmaceuticals, Inc. acquired Allos Therapeutics, Inc.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ALTH
  • CUSIP: N/A
  • Web: N/A
  • Trailing P/E Ratio:
  • P/E Growth:
  • Dividend Yield: 1.0%

Frequently Asked Questions for Allos Therapeutics (NASDAQ:ALTH)

What is Allos Therapeutics' stock symbol?

Allos Therapeutics trades on the NASDAQ under the ticker symbol "ALTH."

Who are some of Allos Therapeutics' key competitors?

How do I buy Allos Therapeutics stock?

Shares of Allos Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

MarketBeat Community Rating for Allos Therapeutics (NASDAQ ALTH)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  24 (Vote Outperform)
Underperform Votes:  30 (Vote Underperform)
Total Votes:  54
MarketBeat's community ratings are surveys of what our community members think about Allos Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Allos Therapeutics (NASDAQ:ALTH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Allos Therapeutics (NASDAQ:ALTH)
No equities research coverage for this company has been tracked by


Earnings History for Allos Therapeutics (NASDAQ:ALTH)
Earnings by Quarter for Allos Therapeutics (NASDAQ:ALTH)
Earnings History by Quarter for Allos Therapeutics (NASDAQ ALTH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2012($0.09)($0.01)ViewN/AView Earnings Details
11/3/2011($0.16)($0.11)ViewN/AView Earnings Details
8/4/2011($0.14)$0.02ViewN/AView Earnings Details
5/10/2011($0.15)($0.14)ViewN/AView Earnings Details
3/3/2011($0.18)($0.17)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Allos Therapeutics (NASDAQ:ALTH)

No earnings estimates for this company have been tracked by


Dividend History for Allos Therapeutics (NASDAQ:ALTH)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Allos Therapeutics (NASDAQ:ALTH)
No insider trades for this company have been tracked by


Headline Trends for Allos Therapeutics (NASDAQ:ALTH)
Latest Headlines for Allos Therapeutics (NASDAQ:ALTH)
No headlines for this company have been tracked by



Allos Therapeutics (ALTH) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by Staff